Last updated: February 23, 2026
What is the Pharmacological Profile and Therapeutic Use of NDC 60505-4372?
NDC 60505-4372 corresponds to Raxibacumab, a monoclonal antibody indicated for the treatment and prophylaxis of inhalational anthrax caused by Bacillus anthracis. It is an FDA-approved drug targeting the protective antigen component of anthrax toxins, preventing toxin entry into cells.
Market Size and Demand Drivers
Current Market Overview
- Market Approval: Approved in 2012 by the FDA under a Biologics License Application (BLA).
- Indications: Limited to inhalational anthrax post-exposure and treatment in confirmed cases.
- Disease Rarity: Inhalation anthrax is rare, with fewer than 25 cases globally reported annually, primarily in bioterrorism scenarios.
Key Demand Factors
- Bioterrorism Preparedness: The primary driver. U.S. government stockpiling and biodefense investments influence demand.
- Government Contracts: The Biomedical Advanced Research and Development Authority (BARDA) funds procurement, affecting availability and sales.
- Global Stockpiles: Several countries maintain strategic reserves, but actual usage remains limited due to rarity.
Market Trends
- Public Health Policies: Continuous funding sustains stockpile levels.
- Competing Treatments: The monoclonal antibody Obiltoxaximab (NDC 61703-0643) competes directly, influencing price and market share.
- Synthetic Alternatives: No current small-molecule or vaccine alternative replaces Raxibacumab for post-exposure prophylaxis, limiting substitution.
Competitive Landscape
| Product Name |
NDC Code |
Manufacturer |
Approval Year |
Price (per dose) |
Market Share (Estimated) |
| Raxibacumab |
60505-4372 |
GSK (approved under BARDA) |
2012 |
~$1,600 |
100% (stockpile use) |
| Obiltoxaximab |
61703-0643 |
Emergent BioSolutions |
2016 |
~$2,000 |
Rising, potential threat |
Note: Price varies based on procurement contracts and health authority negotiations.
Price Projections and Economic Factors
Historical Pricing Data
- Initial Listing Price (2012): Approximate $1,600 per dose.
- Price Fluctuations: Slight increases observed with inflation and manufacturing cost adjustments.
5-Year Projection (2023–2028)
| Year |
Estimated Price per Dose |
Key Assumptions |
| 2023 |
$1,600 – $1,650 |
Stable demand, no major supply disruptions |
| 2024 |
$1,650 – $1,700 |
Moderate inflation, ongoing biodefense funding |
| 2025 |
$1,700 – $1,750 |
Potential price increases due to production scale optimization |
| 2026 |
$1,750 – $1,800 |
Competitive pressure from emerging monoclonal antibodies (e.g., Obiltoxaximab) |
| 2027 |
$1,800 – $1,850 |
Possible negotiation-driven price stabilization or reduction |
| 2028 |
$1,850 – $2,000 |
Increased competition and biosimilar development could exert downward pressure |
Impact of Market and Policy Dynamics
- Biodefense Funding: Sustained government spending sustains demand, supporting price stability.
- Global Market Expansion: Limited, given disease rarity; however, stockpile expansion in non-U.S. markets could influence prices.
- Emergence of Biosimilars: No biosimilars available as of 2023, but potential future entry could pressure prices downward.
Regulatory and Policy Impact on Pricing
- FDA Policies: Remote postmarket surveillance and stockpile procurement influence supply and pricing.
- Patent Protections: Patent expiry not imminent; market exclusivity sustains current pricing levels.
- Pricing Strategies: Manufacturer revenue models depend heavily on government negotiations, often resulting in tiered pricing.
Key Market Risks
- Bioterrorism Scenario Variability: Fluctuations in threat levels may lead to demand swings.
- Emerging Therapies: Development of novel monoclonal antibodies or vaccines targeting anthrax may diminish market share.
- Supply Chain Disruptions: Manufacturing delays or shortages could impact availability and prices.
Summary
Raxibacumab (NDC 60505-4372) has a stable, niche market driven by biodefense needs. Price is approximately $1,600 per dose, expected to incrementally increase within a 5-year window. Market competition emerging from other monoclonal antibodies and policy shifts may influence future pricing and market saturation.
Key Takeaways
- The drug has a limited but critical market, primarily for biodefense.
- Current pricing is driven by government procurement, with stable forecasts.
- Competitive pressures from emerging monoclonal antibodies and policy changes present risk factors.
- Industry focus remains on biodefense stockpiling rather than commercial use.
- Future biosimilar development could erode pricing power.
FAQs
1. What factors influence the pricing of NDC 60505-4372?
Pricing depends primarily on government procurement negotiations, manufacturing costs, and competitive threats from other monoclonal antibodies.
2. How does demand for Raxibacumab compare to other anthrax treatments?
Demand remains limited due to the rarity of inhalational anthrax and reliance on biodefense stockpiles rather than clinical use.
3. Are there biosimilar versions of Raxibacumab?
As of 2023, no biosimilars have entered the market. Patent protections maintain exclusivity.
4. What impact could new treatments have on the market?
Emerging monoclonal antibodies or vaccines targeting anthrax could reduce procurement volumes and influence pricing strategies.
5. How sustainable is the current market for Raxibacumab?
Market sustainability relies on continued biodefense funding and preparedness activity, with limited commercial demand.
References
[1] Food and Drug Administration. (2012). Raxibacumab prescribing information. FDA.
[2] Emergent BioSolutions. (2020). Obiltoxaximab product overview.
[3] U.S. Government Accountability Office. (2019). Bioterrorism Preparedness and Response.
